Hailey Bieber reveals health diagnosis after fan concern for husband Justin
Hailey Bieber has revealed a health diagnosis amid growing worries for Justin Bieber.
The model, 28, took to her Instagram stories to share a photo of herself with the caption: 'Currently have 2 ovarian cysts. If you deal with ovarian cysts I'm right there with ya!'
Ovarian cysts are a health issue Hailey has dealt with previously. In 2022, she posted on Instagram sharing that she had an ovarian cyst 'the size of an apple,' sharing a photo of herself with her shirt pulled up that revealed her stomach.
'I don't have endometriosis or PCOS but I have gotten an ovarian cyst a few times and it's never fun,' she wrote.
At the time, she shared that the condition made her 'feel nauseous and bloated and crampy and emotional.'
'Anyways…I'm sure a lot of you can overly relate and understand,' she continued. 'We got this.'
According to the NHS: 'An ovarian cyst is a fluid-filled sac that develops on an ovary. They're very common and do not usually cause any symptoms. Most ovarian cysts occur naturally and go away in a few months without needing any treatment.'
While most ovarian cysts do not cause symptoms, symptoms can include: pelvic pain – this can range from a dull, heavy sensation to a sudden, severe and sharp pain
pain during sex
difficulty emptying your bowels
a frequent need to urinate
heavy periods, irregular periods or lighter periods than normal
bloating and a swollen tummy
feeling very full after only eating a little
difficulty getting pregnant – although fertility is usually unaffected by ovarian cysts
Hailey's vulnerable post comes amid concerns for her pop star husband, Justin.
The Baby singer has been met with raised eyebrows from fans over the last few months, which ramped up during the annual Coachella music festival in Indio, California.
In a new video, which was posted on Twitter on April 20, the 31-year-old could be seen dancing shirtless in the crowd, smoking what appeared to be a roll-up.
The camera panned across as he moved through the audience and stood beside his 15-year-old brother, Jaxon, who was enjoying the music.
Hailey stepped in and placed her hand on the teenager's back, guiding him to walk in the other direction as the musician continued partying away with a pal.
This comes after the dad-of-one appeared in a TikTok video earlier over the weekend, smoking while partying at an event and looking distinctly out of it.
The footage showed him hunched over and bobbing along loosely to his 2015 song What Do You Mean?
In another social media video from the same night, posted by artist Shaqo, the Sorry superstar seemed unsteady on his feet and even somewhat disoriented.
The new father has been at the center of headlines in recent months, sparking intense fears over his unusual social media posts and public appearances.
However, his team has denied rumours that the singer is using hard drugs. 'The recurring narrative that Justin is using hard drugs is absolutely not true,' they said in a statement to TMZ, sharing that the What Do You mean singer is 'in one of the best places in his life.'
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
'The persistent narrative is exhausting and pitiful and shows that despite the obvious truth, people are committed to keeping negative, salacious, harmful narratives alive,' the message said. More Trending
'[The last 12 months have been] very transformative for him as he ended several close friendships and business relationships that no longer served him.'
Shortly after the denial, Justin shared further videos on social media in which he allegedly smoked from a bong and rapped with a friend about being 'high', while looking glassy-eyed.
'I like a fly guy, I fly high like a magpie, I go high like I'm that guy,' he said towards the camera, while topless.
Got a story?
If you've got a celebrity story, video or pictures get in touch with the Metro.co.uk entertainment team by emailing us celebtips@metro.co.uk, calling 020 3615 2145 or by visiting our Submit Stuff page – we'd love to hear from you.
MORE: David Beckham makes unexpected career move to launch his own chat show
MORE: Kanye West poses with Bianca Censori in risqué photo after his shock incest confession
MORE: British actress knocked over Al Pacino and 'left him on floor' while smuggling food
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
2 hours ago
- Glasgow Times
Children and patients deserve to be safe in schools and hospitals
Around £1.2 billion – part of funding packages announced in last year's autumn budget – will be spent on repairing crumbling schools and hospitals across the country, the Government confirmed. Pupils at 656 schools and sixth forms will benefit from a share of this year's £470 million Condition Improvement Fund (CIF), used for projects like fixing crumbling roofs and removing asbestos. More than 400 hospitals, mental health units and ambulance sites will be handed £750 million to tackle problems such as leaky pipes, poor ventilation and electrical issues. Projects to deliver improvements to schools and hospital buildings will be delivered during the 2025/26 financial year, with the first upgrades to begin this summer, the Government has said. More than 100 schools, nurseries and colleges across England were forced to shut down days before the autumn term in 2023 amid concerns that classrooms and other buildings containing reinforced autoclaved concrete (Raac) were unsafe. Education Secretary Bridget Phillipson said: 'The defining image of the school estate under the previous government was children sitting under steel props to stop crumbling concrete falling on their heads. It simply isn't good enough. 'Parents expect their children to learn in a safe, warm environment. It's what children deserve and it is what we are delivering. Bridget Phillipson (Ben Whitley/PA) 'This investment is about more than just buildings – it's about showing children that their education matters, their futures matter, and this Government is determined to give them the best possible start in life.' Health Secretary Wes Streeting said: 'A decade and a half of underinvestment left hospitals crumbling, with burst pipes flooding emergency departments, faulty electrical systems shutting down operating theatres, and mothers giving birth in outdated facilities that lack basic dignity. 'We are on a mission to rebuild our NHS through investment and modernisation. 'Patients and staff deserve to be in buildings that are safe, comfortable and fit for purpose. Through our Plan for Change, we will make our NHS fit for the future.' A report by the National Audit Office (NAO) in January estimated it would cost around £13.8 billion to address the repairs and remedial work backlog for hospitals and other NHS properties in England, and an additional £13.8 billion to address the maintenance backlog across the school estate. Wes Streeting (Lucy North/PA) The Department for Education has confirmed a £2.1 billion investment for the school estate for 2025/26, almost £300 million more than the previous year. Paul Whiteman, general secretary at school leaders' union NAHT, described the funding boost for school buildings as a 'welcome start'. But he added: 'It is clear that much more Government investment and a long-term plan is needed to restore the school estate to at least a satisfactory condition.' Julia Harnden, funding specialist at the Association of School and College Leaders (ASCL), said: 'The wider problem is that there is a massive £13.8 billion maintenance backlog across the school estate and we are still nowhere near the level of investment needed to address this. 'The fact that schools and sixth form colleges have to bid for funding for urgent repairs and maintenance is in itself a sign of the inadequacy of overall investment and is effectively an annual exercise in papering over the cracks.'
North Wales Chronicle
3 hours ago
- North Wales Chronicle
New AI test could end ‘postcode lottery' for ‘game changer' prostate cancer drug
A study has found the technology can show medics the exact patients who will benefit most from a 'game changer' drug. Abiraterone is a type of hormone therapy that works by blocking the production of testosterone, the hormone that fuels the growth of prostate cancer. It is approved for use on the NHS in England for patients with advanced prostate cancer which has come back and spread to other parts of the body. However, it is not approved for men who are newly diagnosed with high-risk prostate cancer that has not yet spread, despite it being available for these patients in Scotland and Wales for the past two years. The new test, developed by Artera, uses AI to pick up features invisible to the human eye on images of tumour samples. The study, led by The Institute of Cancer Research, London, and University College London (UCL), ran the test on biopsy images from more than 1,000 men who took part in the Stampede trial. Patients were given a score of either biomarker-positive or biomarker-negative. Researchers found abiraterone reduced the risk of death among biomarker-positive patients from 17% to 9%. In biomarker-negative patients, the drug cut death risk from 7% to 4%, with researchers suggesting this indicates these men would benefit from standard therapy. Nick James, a professor of prostate and bladder cancer research at The Institute of Cancer Research, London, and consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, is chief investigator of Stampede and co-led the new study. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy. 'Access to this life-extending drug is currently a postcode lottery – with those living in Scotland and Wales able to receive the treatment for free. 'The NHS in England has previously decided that it would be too expensive to offer the drug. Since the patent expired in 2022, abiraterone costs just £77 per pack – compared with the thousands of pounds that new drugs cost. 'Previous research by my team has shown that preventing cancer relapses for these men would save more money than the drug costs to purchase. 'I truly hope that this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision not to fund abiraterone for high-risk prostate cancer that has not spread.' Prof James also highlighted that while abiraterone can have 'spectacular' results, it does have side effects. 'Abiraterone has already hugely improved the outlook for hundreds of thousands of men with advanced prostate cancer,' he said. 'We know that for many men with cancer that has not yet spread, it can also have spectacular results. 'But it does come with side effects and requires additional monitoring for potential issues with high blood pressure or liver abnormalities. 'It can also slightly increase the risk of diabetes and heart attacks, so knowing who is most likely to benefit is very valuable.' Experts hope the findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, may lead to a change in the availability of abiraterone in England. Prof Kristian Helin, chief executive of The Institute of Cancer Research, said the drug has been a 'game changer for treatment of prostate cancer'. 'Alongside our mission to find smarter, kinder treatments, we must ensure we are matching the right drugs to the right patients,' he added. 'This research, using artificial intelligence, provides an innovative route to testing prostate cancer patients to determine their treatment. 'I hope that this can be implemented so that all men with prostate cancer who will benefit from abiraterone can do so.' Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'Prostate Cancer UK has been calling on the UK Government to approve this life-saving, cost-effective drug for over two years. 'These exciting results suggest a way to make this an even more cost-effective approach. 'We therefore echo the researchers' urgent call for abiraterone to be made available to those men whose lives it can save – men who, thanks to this research, we can now identify more precisely than ever before.' A Department of Health and Social Care spokesperson said: 'We understand the frustration and upset of patients who cannot access this treatment. 'Abiraterone is available for some NHS patients in England with metastatic prostate cancer, and a decision to extend its use will be kept under review.'
Sky News
3 hours ago
- Sky News
New blood test to 'revolutionise' NHS cancer treatment
A new ultra-sensitive blood test which can detect tiny fragments of tumour DNA could be "revolutionary" for NHS patients. Thousands of patients will be offered liquid biopsies, which can help fast-track lung cancer patients to receive targeted treatments. Tissue biopsies are used to confirm a diagnosis of lung cancer and samples can be sent for genomic testing. But liquid biopsies allow for results much faster, and can show patients if they have mutations. Rebeca Proctor, 41, was treated a suspected chest infection last December. After she began coughing up blood, she was diagnosed with stage four cancer - which she called a "punch to the gut". "I was scared - I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children - it was just heartbreaking to think about," the mother of four from Carlisle said. A liquid biopsy showed she had an ALK genetic mutation of her non-small-cell lung cancer. A tissue biopsy took ten days longer to confirm the same result, but in the meantime she could begin a targeted treatment. New medication has "given me my life back", she says. "I'm taking it day-by-day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back," she said. "I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading - we'll keep fighting this and dealing with what's been thrown at us." Breast and lung cancers are two of the most common in England - around 90,000 people are diagnosed with one of them each year. Potential to 'scan' the body in a single blood test NHS England will become the first health service in the world to roll-out a "blood-test first" approach to diagnosing lung cancer, and it follows a successful pilot of the testing last year. Up to 15,000 patients could benefit. The NHS has also said it is expanding testing in advanced breast cancer, with several genetic variations now being screened for. It could save the health service up to £11m per year in lung cancer care. Professor Peter Johnson, NHS national clinical director for cancer, said it would enable patients to receive "more targeted and kinder care", as it would enable some to avoid more intensive treatments - such as chemotherapy - in place of a more targeted approach. "Liquid biopsies are leading us into a new era of personalised cancer care and it's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country," he said. Liquid biopsies, he added, have the potential to "scan" the body in a single blood test. Professor Dame Sue Hill, Chief Scientific Officer for England, said: "This testing is transforming care and helping clinicians match patients earlier especially when cancer tissue may not be available with potentially life-extending targeted therapies rapidly and with greater precision." The health secretary called it an "incredibly exciting new test" that could save countless lives. "It is just the latest example of this government combining the compassionate care of our National Health Service with the ingenuity of Britain's leading scientific minds to revolutionise cancer care," Wes Streeting said.
